Hello, everyone, and welcome back. We hope your weekend was relaxing. Now, of course, the routine returns as meetings and deadlines loom. At least the heat wave has broken, as measured by a rare, cool breeze now wafting through the Pharmalot corporate campus. So please join us for the mandatory cup of stimulation as we prepare for another day. One note: we will be speaking later onan industry panel, so please excuse the interruption in our usual schedule. Meanwhile, have a good one and stay in touch....
Onyx Posts Positive Results For Cancer Drug (Associated Press)
Sanofi Cuts Forecast After FDA Approves Generic Lovenox (Bloomberg News)
The Brilinta Guessing Game As FDA Panel Nears (Reuters)
Eisai Gets Boost From FDA OK For Higher-Dose Aricept (PharmaTimes)
Genzyme Is Seen As More Attractive To Sanofi Than Glaxo (Reuters)
Dr. Reddy's Rules Out Stake Sale To Glaxo (Financial Express)
US Senate Passes Bill Without Pay-To-Delay Provision (Bloomberg News)
FDA Panel Rejects Agency Plan For Opioid Abuse (Associated Press)
Australia Urged To Have Transparent Flu Contracts (ABC News)
Ampac Response To Plant Problems Is Insufficient (InPharma-Technologist)
What Is Future For Exelixis? (Seeking Alpha)
Pfizer Recalls Terramycin Animal Health Med (High Plains/Midwest AG Journal)
3 Comments
I'm disappointed that pay to delay was removed from the bill. Is this a dead issue, or will it be put back on the table later?
Re: Curbing Pain Killer Abuse
Yay, a way to take something old and make it new and costly again. This will result in new patents, yes?
Does it really make sense to change these drugs for responsible users because of abusers? It's a little like limiting certain foods because some people over-indulge. Or making all cars with a max speed of 25mph because some people drive recklessly. If people want to get high they will. Maybe they should do this with the prescription drugs kids are selling to their buddies at school for a few bucks a pill (ritalin, adderall, etc.).
"The companies most likely to be impacted by new regulations include Purdue Pharmaceuticals, maker of the blockbuster pill OxyContin, and King Pharmaceuticals, which markets Embeda morphine capsules."
Do Purdue and King get the first stab at new patents to reduce the negative impact on their companies?
Remember this Condor? "I don’t think you mean to suggest that FDA would wrongly order a drug off the market to improperly benefit a favored competitor to that company, do you?"
Maybe not intentionally. I do wonder who brought up changing these products though, received contributions, stock holdings, and such.
Disclaimer ~ I don't use these products. __________________
Re: Terramycin, has FDA not reapproved the provider because they have not yet gotten around to it, or did they delay for some other reason?
Think I misunderstood this situation, in part. Upon reading again, this appears to be about drugs that did precicely what I was complaining about, reformulating for re-patent for extended use. My sincere apologies. Correct me if I'm not getting this.